



## **Drug Utilization Review Board Meeting Minutes**

November 9, 2021

Webex and In-person Meeting

DUR Board Members in attendance: Kevin Borchert, RP; Tim Bourke, RP; Charlie Moore, RP; Susan Howard, MD; Anthony Ross, MD; Phil Vuchetich, RP;

DUR Board Members not in attendance: Bruce Houghton, MD; Robert Wergin, MD; David Randolph, RP.

DHHS attendees: Ken Saunders, RP; Leah Spencer, RN; Dianne Garside, RP; Spencer Moore, RP

Contracted attendees: Nikia Bennette-Carter, RP, Magellan Rx Management, Jenni Pandak, Magellan RX Management; Jamie Benson, RP, Nebraska Total Care; Maria Martin, RP, Nebraska Total Care; Shannon Nelson, RP, Healthy Blue Nebraska; Bernadette Ueda, RP, United Health Care.

Numerous Public visitors were in attendance per Webex webinar and in person.

### **I. Call to Order:**

The meeting was called to order by Ken Saunders on November 9, 2021 at 6:30 pm CST. Members and attendees were welcomed. The Open-Meetings Act was reviewed and a copy is available on the Nebraska Medicaid Pharmacy website.

### **II. Conflict of Interest**

No conflicts of interest were declared.

### **III. Agenda Approval**

The November 9, 2021 meeting agenda was presented and accepted. Motion by Ross and second by Bourke. Unanimous vote in the affirmative.

### **IV. Approval of Meeting Minutes September 14, 2021**

The Meeting Minutes from the September 14, 2021 DUR Board meeting were reviewed for grammar, spelling, and other edits. Motion by Borchert and second by Bourke to approve the

minutes as presented. The minutes were voted upon and passed as presented by the DUR Board members.

#### **V. Update on Discussions from Previous Meeting (September 2021)**

Ivermectin use was discussed during the September 2021 DUR Board meeting. The conversation continued this meeting.

#### **VI. Special Topics:**

##### **A. Pain**

Saunders brought up the annual CMS Survey that should be resulted by the end of the calendar year. This will allow Nebraska to view the other states' MME values. The question has been posed in the past by the DUR Board members where Nebraska is in MME value versus the other states and how is it that some states do not seem to be as aggressive as Nebraska is in the tapering of the MME values. Once the annual survey is published, the DUR Board will visit this in depth. Saunders will add this to the Agenda once it is made public.

##### **B. DUR Board Updates**

Saunders reminded the DUR Board that the purpose of the DUR Board is to find areas of interest and topics for study by the DUR Board. The DUR Board should think of areas to study, drug classifications to review, and new drugs to be reviewed by the DUR Board.

#### **VII. Retrospective DUR**

##### **A. Old Business – Current Business**

There was nothing to review or discuss in this section.

#### **VIII. Prospective DUR**

##### **A. New Business**

##### **B. Human Growth Hormone**

[https://nebraska.fhsc.com/Downloads/NEcriteria\\_GH.pdf](https://nebraska.fhsc.com/Downloads/NEcriteria_GH.pdf)

[https://nebraska.fhsc.com/Downloads/NEfaxform\\_GH.pdf](https://nebraska.fhsc.com/Downloads/NEfaxform_GH.pdf)

The annual review for the Human Growth Hormone criteria and prior authorization fax form were reviewed and discussed. There were no suggestions or update information requested. Borchert motioned for approval and Moore seconded. Update to prior authorization fax form and criteria passed with Bourke as the only “no” vote.

#### **IX. Future Meeting Dates**

The next DUR Board meeting will be on Tuesday January 11, 2022. Saunders reminded everyone that the January meeting will probably be in-person only. A virtual meeting option *may* be available if the Governor reestablishes the Health Emergency. Please watch the Nebraska Medicaid DUR Board website for meeting information, Agenda items and the DRAFT Minutes. The DUR Board meeting will begin at 6:30 PM CST, with dinner for the members at 6:00 PM CST.

The complete list of future dates for 2022 were discussed and are as follows: January 11, 2022; March 8, 2022; May 10, 2022; July 12, 2022; September 13, 2022; and November 15, 2022. A motion by Moore with a second by Howard was made and voted upon By the DUR Board to accept the 2022 meeting schedule.

**X. Concerns & Comments**

There were some comments by some of the DUR Board members, DHHS Staff, MCO's, or Public members. Saunders did want to remind everyone that the annual CMS Survey completed in the early Fall 2021, includes pain information (MME data). Once the Survey results are published, he will bring to the DUR Board members the nationwide results for examination and discussion by the DUR Board. The MCO's mentioned Stimulant use in patients and wanted to discuss the practice of including a diagnosis with the prescription. MLTC will review the practice and share the findings during the meeting in January 2022.

**X. Adjournment**

A motion was made by Bourke to adjourn the meeting. A second was made by Borchert. The vote was unanimously approved. The meeting was adjourned at 6:55 PM.